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Background. Plasma and urinary levels of D-lactate have been linked to the presence of diabetes. Previously developed techniques
have shown several limitations to further evaluate D-lactate as a biomarker for this condition. Methods. D- and L-lactate were
quantiﬁed using ultraperformance liquid chromatography tandem mass spectrometry with labelled internal standard. Samples
were derivatized with diacetyl-L-tartaric anhydride and separated on a C18-reversed phase column. D- and L-lactate were analysed
in plasma and urine of controls, patients with inﬂammatory bowel disease (IBD), and patients with type 2 diabetes (T2DM).
Results. Quantitative analysis of D- and L-lactate was achieved successfully. Calibration curves were linear (r2 > 0.99) over the
physiological and pathophysiological ranges. Recoveries for urine and plasma were between 96% and 113%. Inter- and intra-assay
variations were between 2% and 9%. The limits of detection of D-lactate and L-lactate in plasma were 0.7µmol/L and 0.2µmol/L,
respectively. The limits of detection of D-lactate and L-lactate in urine were 8.1nmol/mmol creatinine and 4.4nmol/mmol
creatinine, respectively. Plasma and urinary levels of D- and L-lactate were increased in patients with IBD and T2DM as compared
with controls. Conclusion. The presented method proved to be suitable for the quantiﬁcation of D- and L-lactate and opens the
possibility to explore the use of D-lactate as a biomarker.
1.Introduction
There are several conditions in which D-lactate can become
increased in blood and urine in humans [1]. Recent studies
demonstrated increased levels of D-lactate in diabetes and
in infection, ischemia, and trauma, suggesting the use of D-
lactate as a biomarker. However, to further explore the use of
D-lactate as such a biomarker, there is a need of an improved
method for analysing D-lactate.
Lactate has two optical isomers, L-lactate and D-lactate
(Figure 1(b)). L-lactate is the most abundant enantiomer of
lactate. It is formed mainly during anaerobic glycolysis by
conversion of pyruvate to L-lactate by lactate dehydrogenase
[2]. D-lactate is often considered as the nonphysiological
counterpart of L-lactate [1]. Under physiologic conditions,
the concentration of D-lactate is a 100-fold lower when com-
pared to L-lactate [3]. The origin of D-lactate in human
metabolismisthoughttobederivedfromtwomajorsources,
namely, degradation of methylglyoxal into D-lactate by the
glyoxalase pathway and production by intestinal bacteria.
Indeed, disturbances in these metabolic pathways are asso-
ciated with increased levels of D-lactate [3–7]. Although2 Experimental Diabetes Research
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Figure 1: Representative chromatograms of D- and L-lactic acid derivatives(a). (a) Internal standard [13C3]-L-lactate chromatogram
(435µmol/L, 72pmol). (b) Representative chromatogram of a standard solution of D- and L-Lactate (351µmol/L, 58.2pmol, 501µmol/L,
and 83.0pmol, resp.) and molecular structures of optical isomers L- and D-lactates. (c) Representative chromatogram of a urine sample
(D- and L-Lactate; 14.1µmol/L, 2.3pmol, 74.6µmol/L, and 12.4pmol, resp.). (d) Representative chromatogram of a plasma sample (D- and
L-Lactate; 11.2µmol/L, 1.9pmol, 1375.0µmol/L, and 227.7pmol, resp.). (a)Injection volume: 2µL.
some enzymes capable of metabolizing D-lactate have been
described[8],itsmetabolismisveryineﬃcient,andD-lactate
is mainly excreted in urine [1].
Methylglyoxal is a highly reactive compound formed in
the process of glycolysis and lipid peroxidation. Methylgly-
oxal is increased in diabetes and is a major precursor in the
formation of advanced glycation endproducts [9]. Methyl-
glyoxal is degraded by the glyoxalase system resulting in D-
Lactate. D-lactate in plasma and urine has been shown to be
increased in patients with diabetes [3, 7]. D-lactate can be
used as a reﬂection of methylglyoxal and is much easier to
measure than the very reactive methylglyoxal.
In the colon, many commensal bacteria produce D-lac-
tate as a result of anaerobic glycolysis. Under physiological
circumstances, this D-lactate is further metabolized by the
commensal bacteria to acetate. Therefore, D-lactate pro-
duced in the intestinal tract does not signiﬁcantly contribute
to levels of D-lactate in the systemic circulation under
physiological circumstances [10]. However, under patho-
logic conditions, systemic D-lactate levels may rise due to
intestinal production by bacteria. In patients with ulcerative
colitis, gut ischemia, and appendicitis, increased levels of
D-lactate have indeed been demonstrated [4–6]. The most
extreme example of impaired gut permeability and bacterial
overgrowth is short bowel syndrome, which is associated
with D-lactate acidosis [10].
So far, D- and L-Lactate have been analysed by several
diﬀerent techniques ranging between chiral stationary phase
liquid chromatography using UV or ﬂuorescence detection
[3, 11–15], enzymatic assays [7, 16–21], gas chromatog-
raphy mass spectrometry (GC/MS) methods [22, 23], liq-
uid chromatography mass spectrometry (LC/MS) methods
[24, 25], and reversed phase liquid chromatography using
ﬂuorescence detection [26]. However, these techniques haveExperimental Diabetes Research 3
Table 1: MRM settings.
Component Parent ion (m/z) Daughter ion (m/z) Collision energy (eV) Dwell (secs)
[13C3]-L-lactate 307.95 91.95 8.0 0.1
D-lactate 304.95 88.95 8.0 0.1
L-lactate 304.95 88.95 8.0 0.1
several shortcomings such as low sensitivity [11, 24, 27],
large sample volume [19, 21, 22], complex chromatographic
systems [3, 12, 13], and long run times [3, 11, 26, 27]. To
further explore the use of D-lactate as a biomarker, there is a
need of an improved method for analysing D-lactate.
In this paper, we describe a highly sensitive, speciﬁc
and fast ultraperformance liquid chromatography (UPLC)
tandemmassspectrometry(MS/MS)methodfortheanalysis
of D- and L-Lactate in plasma and urine without the need
of a chiral stationary phase. We achieved a signiﬁcant im-
provement over the methods described in the literature and
obtained a strong tool for the analysis of D- and L-Lactate
in large studies. With this method, we measured plasma
and urine concentrations of D- and L-Lactate in controls,
patients with inﬂammatory bowel disease (IBD), and in
patients with type 2 diabetes (T2DM).
2.MaterialsandMethods
2.1. Chemicals and Reagents. L(+)-lactate (98%) and dichlo-
romethane (≥99.9%) were obtained from Sigma-Aldrich.
Ammonia solution (25%) and acetic acid anhydrous (100%)
were obtained from Merck. Formic acid (p.a.), (+)-O,O -
diacetyl-L-tartaric anhydride (≥97%) (DATAN) and lithium
D-lactate (≥99%) were obtained from Fluka. Water and ace-
tonitrile (ULC-MS grade) were obtained from Biosolve.
[13C3]-Sodium L-lactate (20%, w/w in water) was obtained
from Cambridge Isotope Laboratories.
2.2. Chromatographic Conditions. Samples were analysed by
reversed phase LC-tandem MS using an Acquity UPLC BEH
C18 analytical column (100 × 2.1mm, 1.7µm, Waters).
Detection was carried out using a Xevo TQ tandem mass
spectrometer (Waters), which was operated in negative
multiple-reaction-monitoring (MRM) mode. UPLC anal-
ysis was performed using a binary gradient at a ﬂow of
0.5mL/min using an Acquity UPLC (Waters). Solvent A was
1.5mM ammonium formate (pH = 3.6), and solvent B was
acetonitrile. A linear gradient was started at 99.5% solvent
A, which was changed within 3 minutes to 97% solvent A.
After cleaning the column with 40% solvent B during 2
minutes, the column was equilibrated for 1 minute at the
initial composition. Injection volume was 2µL, and column
temperature was set at 31◦C. Samples were kept at 6◦C.
Chromatograms were acquired and processed with Masslynx
V4.1 SCN 644 (Waters).
2.3. Mass Spectrometry Conditions. MRM transitions were
optimised using direct infusion of D-lactate (500µmol/L),
[13C3]-L-Lactate (400µmol/L), and L-lactate (1000µmol/L)
standardsolutionintothetandemMSataﬂowof20µL/min.
Optimal conditions for all parents were found at a capillary
voltage of 1.5kV and a cone voltage of 10V. The source and
desolvation temperature were 150 and 450◦C, respectively.
The cone gas ﬂow and desolvation gas ﬂow were 0 and 800
l/hour, respectively. To establish the most sensitive daughter
ions, the collision energy was set at 8eV with a collision
gas ﬂow of 0.15mL/min. Table 1 shows the optimised MRM
settings.
2.4. Plasma and Urine Samples. T h r e eg r o u p sw e r es e l e c t e d
for D- and L-Lactate measurements. Diabetic individuals
and nondiabetic controls were sex- and age-matched subsets
recruited from the cohort study of diabetes and atheroscle-
rosis in Maastricht (CODAM). The characteristics of these
subjects have been described in detail elsewhere [28]. In
short, the control group (n = 52 ) was 55.8 ± 0.7y e a r so l d ,
46% female, and had an HbA1C of 5.6 ± 0.1% and a fasting
plasma glucose of 5.2 ± 0.1 mmol/L. Group 2, the patients
with T2DM (n = 52 ), were 56.3±0.6 years old, 39% female,
and had an HbA1C of 6.9±0.2% and fasting plasma glucose
of 8.0 ± 0.2 mmol/L. Group 3 consisted of patients with
IBD in remission: 32 plasma samples (52.3 ± 8.6 years, 44%
female)and34urinesamples(54.6±14.1years,59%female).
These samples were recruited from the outpatient-clinic of
the Maastricht University Medical Center.
For comparison of the proposed UPLC tandem MS
methodwiththeenzymaticmethod, weanalysedplasmaand
urinary D-lactate, with both methods, in rat samples. These
animals were described in details elsewhere [29].
2.5. Plasma Sample Preparation. To 25 µL of internal stan-
dard solution (containing 434.75µmol/L [13C3]-L-lactate)
25µL of plasma was added. Samples were mixed thoroughly
and subsequently deproteinized with 600µLo fam i x t u r e
of methanol:acetonitrile (1:1, by volume) and centrifuged
at room temperature during 10 minutes at 14000rpm. The
supernatant was pipetted into a reaction vial and evaporated
todrynessunderagentlestreamofnitrogenatatemperature
of50◦C.FiftymicrolitersoffreshlymadeDATAN(50mg/mL
dichloromethane:acetic acid (4:1, by volume)) was added.
The vial was capped, vortexed, and heated at 75◦Cf o r3 0
minutes. After 30 minutes, the vial was allowed to cool down
to room temperature, and the mixture was evaporated to
dryness with a gentle stream of nitrogen. The derivatized
residue was reconstituted with 150µL acetonitrile:water
(1:2, by volume).
2.6. Urine Sample Preparation. Twenty ﬁve microliters of
internalstandardsolution(containing434.75µmol/L[13C3]-
L-lactate),25µLurine,and300µLofmethanolwerepipetted4 Experimental Diabetes Research
Table 2: Linearity tested in diﬀerent matrices.
Matrix Slope(a) Y-intercept r2 Concentration range (µmol/L)
D-lactate
Water 1.2927 −4.5 0.9971 0–105
Plasma A 1.4307 21.2 0.9987 0–105
Plasma B 1.3820 51.3 0.9991 0–105
Plasma C 1.5037 31.9 0.9990 0–105
Mean 1.4023
CV(%) 6.3
L-lactate
Water 0.7768 −4.9 0.9996 0–3008
Plasma A 0.7566 1032 0.9998 0–6016
Plasma B 0.7164 996 0.9997 0–6016
Plasma C 0.7534 1346 0.9997 0–3008
Mean 0.7502
CV(%) 3.2
D-lactate
Water 1.1265 −15.4 0.9999 0–702
Urine A 1.1092 105.24 0.9984 0–351
Urine B 1.1114 99.7 0.9999 0–702
Urine C 1.0287 69.8 0.9992 0–351
Mean 1.094
CV(%) 4.04
L-lactate
Water 0.7967 0.2 0.9998 0–1002
Urine A 0.8039 60.4 0.9995 0–501
Urine B 0.7918 48.6 0.9995 0–1002
Urine C 0.7749 135.0 0.9993 0–501
Mean 0.7967
CV(%) 1.56
(a)Slope: {concentration (µmol/L)} versus {response = (peak area component/peak area internal standard). ∗Internal standard concentration (µmol/L)}.
into a reaction vial. Samples were mixed thoroughly and
evaporated to dryness under a gentle stream of nitrogen
at a temperature of 50◦C. Fifty microliters of freshly made
DATAN (50mg/mL dichloromethane:acetic acid (4:1, by
volume)) was added. The vial was capped, vortexed, and
heated at 75◦C for 30 minutes. After 30 minutes, the vial
was allowed to cool down to room temperature, and the
mixture was evaporated to dryness with a gentle stream
of nitrogen. The derivatized residue was reconstituted with
300µLacetonitrile:water(1:2,byvolume).
2.7. Method Validation. Linearity of the detection of D- and
L-LactatewastestedinwaterandmatrixbyaddingD-andL-
Lactate standard to water and during preparation of plasma
or urine samples (Table 2). Calibration curves were obtained
by linear regression of a plot of the analyte concentration (x)
versus the peak-area ratio of the analyte/internal standard
area (y). For both the analytes, [13C3]-L-lactate was used as
internal standard.
The lower limit of detection was determined by calculat-
ing the concentration at a signal-to-noise ratio of six (s/N: 6,
injection volume: 2µL).
For recovery experiments, standard solutions of D- and
L-Lactate were added to urine or plasma and subsequently
prepared as described in the sample preparation section.
The intra-assay variation of the method was determined
in two diﬀerent plasma and urine samples (n = 10) analysed
in one batch during one day. The interassay variation of
the method was determined in two diﬀerent plasma and
urine samples divided into batches and analysed during 10
diﬀerent days.
Freeze-thaw stability was tested in two diﬀerent plasma
and urine samples by snap-freezing these samples in liquid
nitrogen and thawing them for 5 subsequent cycles.
To investigate the stability of plasma and urine samples,
stored at 6◦C in the autosampler, replicate injections of two
diﬀerent plasma and urine samples were done every hour
during 24 hours.
2.8. Determination of Fasting Plasma Glucose, Hba1C, and
Urinary Creatinine. After an overnight fast, plasma glucose
concentrations (mmol/L) were measured with a hexokinase
glucose-6 phosphate dehydrogenase method (ABX Diag-
nostics, Montpellier, France). Hba1C (%) was determinedExperimental Diabetes Research 5
by ion-exchange high-performance liquid chromatography
(HPLC) (Bio-Rad, Veenendaal, the Netherlands). Fasting
plasma glucose concentrations and Hba1C were determined
in the CODAM participants only.
Urinary D- and L-Lactate concentrations were expressed
as µmol/mmol creatinine. Creatinine concentration in urine
was analysed using a Beckman LX20 analyser (Beckman
Coulter) based on the Jaﬀ´ e reaction method [30].
2.9. D-Lactate Enzymatic Assay. For method comparison,
an enzymatic-spectrophotometric method, based on the
oxidation of D-lactate to pyruvate by NAD+ in the presence
of bacterial D-lactate hydrogenase, was used [21].
2.10. Statistical Analysis. The method validation data were
expressed as mean and standard deviation (SD). To inves-
tigate agreement between the enzymatic and UPLC tandem
MS method, we used linear regression and a Bland-Altman
plot after log normalisation of the rat urine samples. Limits
of agreement were deﬁned as 2 times the SD. The patient
study data were expressed as mean and standard error of the
mean(SEM).Todetectgroupdiﬀerences,weappliedanalysis
ofvariance(ANOVA)withposthocBonferronicorrection.P
value <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Reversed Phase Chromatography. D- and L-Lactate
DATAN derivatives yielded a baseline separation on a re-
versed phase UPLC column with a retention time of 2.7 min-
utes for D-lactate and 2.5 minutes for L-lactate. Representa-
tive chromatograms are shown in Figure 1.
3.2. Stability of D- and L-Lactate. After 5 freeze-thaw cycles
no change of D- and L-Lactate levels was observed, as tested
in two diﬀerent plasma and urine samples (data not shown).
To make large number of measurements within one run
possible, we tested the stability of D- and L-Lactate when
samples were stored in the autoinjector at 6◦C. D- and L-
Lactate were at least stable for 24 hours, and no degradation
wasobservedafterreplicateinjectionsoftwodiﬀerentplasma
and urine samples (data not shown).
3.3. Linearity, Lower Limit of Detection, Recovery, and Pre-
cision. Linearity of the detection of D- and L-Lactate was
tested in matrix and water. For plasma, the slope, tested
in three diﬀerent plasma samples and in water measured
on diﬀerent days, was 1.4 ± 6.3% (mean ± CV%) for D-
lactate and 0.75 ± 3.2% for L-lactate (Table 2). For urine,
the slope, tested in three diﬀerent urine samples and in water
measuredondiﬀerentdays,was1.09±4.0%forD-lactateand
0.80 ± 1.6% for L-lactate (Table 2). The limits of detection
of D-lactate and L-lactate in plasma were 0.65µmol/L
(108fmol) and 0.2µmol/L (33fmol), respectively. The lim-
its of detection of D-lactate and L-lactate in urine were
8.1nmol/mmol creatinine (40fmol); and 4.4nmol/mmol
creatinine (22fmol) respectively.
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Figure 2:ComparisonofurinaryD-lactateinraturineasmeasured
by UPLC tandem MS and enzymatic method. (a) Correlation
between D-lactate levels measured by UPLC tandem MS and enzy-
matic method. (b) Bland-Altman plot of log-transformed D-lactate
levels as measured by UPLC tandem MS and enzymatic method.
We found recoveries, for urine and plasma, between 96%
and 113% (Table 3). The validation data demonstrated inter-
and intra-assay variations between 2% and 9% (Table 4).
3.4. Comparison of the UPLC Tandem MS Method versus
the Enzymatic Assay. We compared the proposed UPLC-
tandem MS method with the enzymatic assay, by analysing
plasma and D-lactate levels in rat urine with both methods.
However, due to low D-lactate levels in plasma, it was
not possible to analyse these samples with the enzymatic
assay (data not shown). For urine, linear regression of the
data resulted in the equation y = 1.08x + 50.795, with
excellent correlation (r = 0.985) between both techniques
(Figure 2(a)). However, the Bland Altman plot showed that
although in the higher range both techniques are in excellent
agreement, in the lower range considerately higher values
were measured with the enzymatic technique as compared
with the UPLC tandem MS method (Figure 2(b)).
3.5. Comparison of Urinary and Plasma D- and L-Lactate
Concentration between Controls, Individuals with T2DM, and
Individuals with IBD. We next investigated D- and L-Lactate
plasma and urine concentration of nondiabetic controls,6 Experimental Diabetes Research
∗
0
4
8
12
16
20
Controls IBD T2DM
(
µ
m
o
l
/
L
)
D-lactate in plasma (mean ± SEM)
(a)
∗
0
400
800
1200
1600
2000
Controls IBD T2DM
(
µ
m
o
l
/
L
)
L-lactate in plasma (mean ± SEM)
(b)
0
1
2
3
4
5
Controls IBD T2DM
∗
D-lactate in urine (mean ± SEM)
(
µ
m
o
l
/
m
m
o
l
 
c
r
e
a
t
i
n
i
n
e
)
(c)
∗ ∗
0
5
10
15
Controls IBD T2DM
(
µ
m
o
l
/
m
m
o
l
 
c
r
e
a
t
i
n
i
n
e
)
L-lactate in urine (mean ± SEM)
(d)
Figure 3: Urinary and plasma D- and L-Lactate concentrations of controls, patients with inﬂammatory bowel disease (IBD), and patients
with type 2 diabetic patients (T2DM). Data are presented as Mean ± SEM: (∗P<0.05).
patients with IBD, and T2DM patients (Figure 3). In healthy
controls, D- and L-Lactate concentrations were 8.0 ± 0.6 and
1044.8±36.7µmol/Linplasma,respectively,and1.1±0.2and
6.3 ± 0.9µmol/mmol creatinine in urine, respectively (mean
± SEM). In IBD patients, levels of D- and L-Lactate were
higher, when compared to the nondiabetic control group in
both plasma (10.7±1.2 and 1172.4±74.6µmol/L, resp.) and
urine(3.1 ±0.8and11.8 ±1.4µmol/mmolcreatinine,resp.),
which was signiﬁcant for urinary L-lactate.
In T2DM patients, the concentrations of D- and L-
Lactate were signiﬁcantly higher in plasma (12.3 ± 0.8a n d
1534.7 ± 67.5µmol/L, resp.) and urine (3.4 ± 1.0a n d1 2 .1 ±
2.0µmol/mmol creatinine, resp.). Both plasma and urinary
D-lactate levels, as determined in T2DM and controls,
correlated with HbA1C (r = 0.392, P<0.001 and = 0.421,
P<0.001, resp.) and fasting plasma glucose (r = 0.360,
P<0.001 and r = 0.416, P<0.001, resp.).
4. Discussion
We describe here a rapid, sensitive, and highly speciﬁc me-
thodforthesimultaneousdeterminationofD-andL-Lactate
in plasma and urine by UPLC MS/MS. The derivatisation
of D- and L-Lactate with DATAN makes it possible to sepa-
rate both enantiomers on a reversed-phase-based analytical
column. This results in a robust chromatographic system
without the need of a column-switching or solid phase
extraction (SPE) presample cleanup. We found that urinary
and plasma levels of D- and L-Lactate were signiﬁcantly
increased in T2DM as compared with nondiabetic controls.
In addition, we observed higher L- and D-Lactate levels in
patients with IBD, but only signiﬁcant for urinary L-lactate.
Many other techniques have been used to quantify D-
and L-Lactate, with several disadvantages, such as long run
times [3,11,26,27],l a r g es a m p l ev o l u m e[19,21,22,24,27],
a column-switching preseparation technique [3, 12, 13], or
low sensitivity [11, 24, 27]. Moreover, a disadvantage of the
enzymaticmethodisthatitisnotpossibletomeasureD-and
L-Lactate in a single run.
Chiral stationary phase liquid chromatography has been
applied for the enantiomeric separation of D- and L-Lac-
tate [11, 14, 25]. SPE or prereversed phase liquid chro-
matographic separation is obligatory for good chiral chro-
matographic performance [3, 12, 13, 31]. Furthermore,Experimental Diabetes Research 7
Table 3: Recovery data for plasma and urine.
Plasma Mean (SD) µmol/L CV, % Recovery, %
D-lactate added(a)
µmol/L (n = 5)
0 8.1 (0.2) 2.9 —
52.7 67.3 (1.2) 1.8 112.4
105.4 127.7 (3.7) 2.9 113.5
L-lactate added(a)
µmol/L (n = 5)
0 1365 (44.6) 3.3 —
1504 2931 (26.2) 0.9 104.2
3008 4443.2 (125.1) 2.8 102.3
Urine(b) Mean (SD) µmol/mmol
creatinine CV, % Recovery, %
D-lactate added(a)
µmol/L (n = 5)
0 0.91 (0.03) 3.4 —
98.8 8.03 (0.10) 1.3 110.9
197.6 14.34 (0.29) 2.0 104.7
L-lactate added(a)
µmol/L (n = 5)
0 4.84 (0.13) 2.6 —
94 10.99 (0.38) 3.5 100.6
188 16.56 (0.14) 0.8 96.0
(a)Addition of 25µL standard solution to 25µL plasma or urine.
(b)Creatinine concentration: 15.4mmol/L.
Table 4: Precision data for D- and L-Lactate in plasma and urine.
Matrix D-lactate mean (SD), µmol/L CV,% L-lactate mean (SD), µmol/L CV,%
Intra-assay, n = 10
Plasma A 13.0 (0.7) 5.1 1265.3 (36.2) 2.9
Plasma B 85.7 (2.5) 2.9 6605.8 (190.4) 2.9
Interassay, n = 10
Plasma A 12.4 (0.6) 5.2 1338.7 (48.8) 3.6
Plasma B 85.4 (3.8) 4.4 6452.6 (245.8) 3.8
D-lactate mean (SD),
µmol/mmol creatinine
L-lactate mean (SD),
µmol/mmol creatinine CV, %
Intra-assay, n = 10
Urine A(1) 0.857 (0.03) 3.8 4.40 (0.27) 6.0
Urine B(2) 16.26 (0.48) 2.9 10.58 (0.60) 5.7
Interassay, n = 10
Urine A(1) 0.718 (0.04) 5.6 3.75 (0.33) 8.8
Urine B(2) 14.90 (1.05) 7.0 8.68 (0.81) 9.3
(1)Urine A, creatinine 15.4mmol/L.
(2)Urine B, creatinine 5.9mmol/L.
the shorter lifetime, higher cost, and diﬃcult selection of
a suitable chiral column [32, 33]h a v em a d ea na l t e r n a -
tive method for enantiomeric separation desirable. More
recently, Cevasco et al. [26] used a reversed phase liquid
chromatography method for separation of D- and L-lactic
acid. However, a run-to-run time of 35 minutes and an
obligatory SPE sample preparation step make this method
less feasible for large cohort studies. Moreover, the used
derivatisation reagent was not commercially available and
had to be synthesised before use.
Anhydrides of tartaric acid were used successfully as
chiral derivatisation reagents of hydroxy acids and other
enantiomeric compounds [34–36]. In this paper, we describe
the derivatisation of the enantiomeric D- and L-Lactate8 Experimental Diabetes Research
with DATAN. This derivatisation step results in a highly
sensitive and speciﬁc D- and L-Lactate derivative which is
baseline separated on a UPLC reversed phase column and
detected with tandem MS. The advantage of this technique,
as compared to the described methods in the literature, is
that there is no need for sample cleanup or preseparation of
the sample matrix, and only 25µL of sample is necessary.
Also the highly eﬃcient and speciﬁc fragments of these
DATAN derivatives generated in the collision cell is an
improvement against the nonderivatized analysis of D- and
L-Lactate with LC/MS [25]. With a run-to-run time of 6
minutes we established a fast and reliable method suitable
for measuring D- and L-Lactate in large cohort studies.
The D- and L-Lactate concentrations we measured in
plasma and urine from healthy controls are in reasonable
agreement with data obtained by other techniques [3, 18, 19,
25]. Indeed, we found an acceptable correlation of the new
UPLC tandem MS method with the enzymatic assay in urine
samples. However, the enzymatic assay is not adequately sen-
sitive for lower levels of D-lactate, as reﬂected in the Bland-
Altman plot. The enzymatic method measures higher levels
of D-lactate than the UPLC tandem MS in the lower range.
D-lactate was not signiﬁcantly increased in patients with
IBDcomparedwithnondiabetic controlsinbothplasmaand
urine. Another study, however, found a signiﬁcant increase
of D-lactate in hospitalised patients with active IBD [6]. This
diﬀerence may be explained by the fact that the patients we
have included were in remission. In addition, due to the
relatively small sample size, the power to detect statistically
diﬀerences was low.
We found a statistically signiﬁcant increase of urine and
plasma levels of D- and L-Lactate in T2DM as compared
with nondiabetic controls. The fact that both D-lactate
and L-lactate are increased in patients with T2DM suggests
that the hyperglycaemic state is an important source of D-
lactate elevations in diabetes. L-lactate is mainly formed
during glycolysis by conversion of pyruvate to L-lactate
by lactate dehydrogenase. D-lactate is an endproduct of
the metabolism of methylglyoxal, formed during hypergly-
caemia, by the glyoxalase pathway [37]. In line with this,
we demonstrate that D-lactate correlates signiﬁcantly with
HbA1C, a marker for prolonged hyperglycaemia. However,
based on our small study, we cannot deﬁnitely conclude
whether D-lactate is merely a reﬂection of methylglyoxal,
gut-ﬂora, or both, as several possible residual confounding
factors such as BMI and gut permeability may explain the
diﬀerences we observed between our patient groups.
M e t h y l g l y o x a li sp r o d u c e di ns m a l la m o u n tf r o mc a r -
bohydrates, fat, and protein metabolism. It is has been
demonstrated that methylglyoxal is the most important
precursor in the formation of advanced glycation endprod-
ucts. Methylglyoxal and methylglyoxal-derived advanced
glycation endproducts are believed to be implicated in the
development of diabetic vascular complications. Because D-
lactateis elevated in diabetes and may be used as an indicator
of methylglyoxal, the measurement of D-lactate needs to
be evaluated in cohort studies with D-lactate as a possible
predictor of diabetic complications. In addition, mechanistic
studies are needed to elucidate the relative contribution of
several metabolic pathways to the total urinary and plasma
D-lactate pool, in both healthy and diabetic individuals.
In conclusion, this speciﬁc measurement of D- and L-
Lactate shows promise in the investigation of diabetes and
metabolic diseases.
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